Long-term study of infigratinib in children with hypochondroplasia
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study is for children with hypochondroplasia who already completed the ACCEL 2/3 trial. It tests the long-term safety and effects of the study drug infigratinib, and gives continued access to the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have finished the ACCEL 2/3 study for hypochondroplasia.
- Girls age 10 or older (or who have started their period) must have a negative pregnancy test.
- You cannot have stopped the ACCEL 2/3 study early.
- Your child must not have reached their final height (or near final height).
- Your child cannot be taking part in any other clinical trial (unless it's run by QED Therapeutics).
- No new medical condition that would need a medicine not allowed in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called infigratinib in children with hypochondroplasia, a form of short stature. It aims to see if the drug can help improve growth and is for children who are still growing.
This study is for children with hypochondroplasia, a condition that causes short stature. It will look at how the condition changes over time and aims to better understand it, with the goal of finding new treatments.
this study is a long-term extension of the main study for the drug which from Bio? bi? whatever? in the name? by?...????
This study observes children with hypochondroplasia to learn more about the condition. It does not involve any treatment—just monitoring and data collection to help future research.
This study tests a daily injection called vosoritide to see if it helps children with hypochondroplasia grow taller. It is for babies and toddlers up to 35 months old who are shorter than average for their age.
This trial studies how well infigratinib works and remains safe for children with achondroplasia. It includes children who already took infigratinib in a prior QED study, and some who are starting treatment for the first time.
Hear when a new Hypochondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.